Nabla
Ambient AI scribe that turns patient visits into clinical notes.
Overview
Nabla is a Paris-founded ambient AI scribe that listens to clinical visits and writes structured notes, coding suggestions, and patient summaries directly into Epic, Oracle Health, athenahealth, and other EHRs, used by 85,000+ clinicians at 150+ health systems.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 31 Aug 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
- Core note generation
- Limited usage
- No card required to start
- Unlimited consultations on paid plans
- EHR integration
- Quote-based
- Tailored models and workflows
- SAML SSO
- Organizational deployment support
Use cases
What you can produce with Nabla
- Structured clinical note (SOAP or custom format) generated automatically within seconds of a consultation
- ICD-10 and medical coding suggestions surfaced in real time during or after the patient encounter
- Patient-friendly visit summary ready for sharing immediately after the appointment, in the patient's selected language
- Custom note templates per specialty or department, adjustable by clinicians via the Nabla dashboard
- EHR-embedded documentation pushed directly into Epic, athenahealth, Oracle Health, or other integrated systems without copy-paste
- Agentic coding and billing audit flags that identify documentation gaps before claim submission
- API access for enterprise health systems building custom clinical workflow integrations via the Nabla Core API
ASEAN Perspective
Nabla in Southeast Asia
Nabla has no confirmed presence, partnerships, or regulatory clearances in ASEAN markets as of mid-2026. Its language support, while marketed broadly, is publicly confirmed for English, Spanish, and French — coverage of regional languages such as Bahasa Melayu, Bahasa Indonesia, Thai, Vietnamese, or Filipino is unverified. ASEAN clinicians working within English-language healthcare settings (such as Singapore's private hospital sector) may find the core ambient transcription useful, but EHR integration support for regional systems like iHIS or local hospital platforms has not been announced. Healthcare AI buyers in the region should assess data residency requirements carefully, as Nabla's infrastructure is US/EU-centric and PDPA or national health-data localisation rules may apply.
Nabla has the best clinical evidence in ambient scribing: a NEJM AI randomized trial across 238 physicians and 48,000+ visits found a statistically significant 9.5% cut in documentation time. Real deployments back it up — University of Iowa Health Care's 5-week pilot logged a 26% burnout-score drop before system-wide rollout, and Carle Health reported 55% of clinicians saving an hour a day. Coverage spans 55+ specialties and 20+ EHR integrations, and the June 2025 Series C ($70M, HV Capital) is pushing the roadmap into coding and nursing agents.
Pricing is now opaque, contract-driven enterprise-only. Nabla hasn't disclosed a post-Series C valuation — the $5.3B figure circulating online is actually Abridge's, a rival, not Nabla's; Nabla's last disclosed mark was roughly $180M at its 2024 Series B.
What people say
Nabla has the clinical paper trail most ambient scribes don't: a NEJM AI randomized controlled trial across 238 physicians and 48,000+ visits found a statistically significant 9.5% reduction in documentation time. That's not a company-commissioned survey — it's a peer-reviewed comparison, and it's a genuine differentiator in a crowded field.
Field results back it up. University of Iowa Health Care's five-week pilot hit 100% adoption and a 26% drop in burnout scores before rolling Nabla out to every clinician system-wide; Carle Health separately reported 55% of clinicians saving at least an hour of documentation time a day. Coverage spans 55+ specialties, 35+ languages, and 20+ EHR integrations including Epic and Oracle Health, and the June 2025 Series C ($70M, led by HV Capital, bringing total funding to $120M) is funding a push into coding agents, pre-charting, and nursing workflows.
Two things to flag before signing anything. First, pricing has moved to opaque, contract-driven enterprise tiers — there's no self-serve number to compare against competitors. Second, the $5.3 billion valuation that circulates in some secondary coverage of Nabla is actually a mix-up: that figure belongs to Abridge, a rival that raised at $5.3B in June 2025. Nabla itself hasn't disclosed a valuation since its Series C; the last public mark was roughly $180M at its January 2024 Series B. Deployment is still overwhelmingly US-based, with no confirmed NHS or APAC contracts yet.
Summary of public user & expert reviews, compiled by RECATOOLS.
Notable facts
- Nabla co-founder Alex Lebrun previously sold two AI companies — VirtuOz to Nuance (2013) and Wit.ai to Facebook (2015) — before founding Nabla, giving the team direct roots in both conversational AI and medical NLP.
- The founding team ran their own UK-based clinics for a full year before writing a single line of product code, to understand physician workflow firsthand.
- Nabla was the first healthcare AI company to publish a CHAI Applied Model Card — a governance transparency disclosure aligned with the Coalition for Health AI standards.
- Yann LeCun, the Turing Award-winning deep learning pioneer, was an early investor in Nabla, and in late 2025 his new research company Advanced Machine Intelligence entered an exclusive partnership with Nabla to build FDA-certifiable agentic clinical AI.
Frequently asked questions
About this listing
This entry was compiled from publicly available data including Nabla's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Nabla unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Nabla directly →
Spotted something out of date? Suggest an update →
Alternatives to Nabla
More in Productivity
